Tonix Pharmaceuticals Holding Corp. 8-K

What Happened
Tonix Pharmaceuticals Holding Corp. announced it dismissed its independent registered public accounting firm, EisnerAmper LLP, effective March 16, 2026. The Audit Committee approved the dismissal. The company filed the Form 8‑K on March 18, 2026 and included a letter from EisnerAmper as an exhibit.

Key Details

• EisnerAmper audited Tonix’s consolidated financial statements for the fiscal years ended December 31, 2025 and December 31, 2024; those audit reports included an explanatory paragraph about continuing losses and negative cash flows raising substantial doubt about the company’s ability to continue as a going concern.
• The dismissal was not due to any disagreement over accounting principles, financial statement disclosure, or auditing scope/procedures.
• During the two most recent fiscal years (2024 and 2025) and the interim period through March 16, 2026, there were no disagreements or “reportable events” with EisnerAmper, other than previously disclosed material weaknesses (from the 10‑Q for the quarter ended June 30, 2024) that were remediated by December 31, 2024.
• The 8‑K does not name a successor auditor.

Why It Matters
A change of independent auditor is a material governance event investors watch because it can signal shifts in financial reporting or oversight. In Tonix’s case, the company and EisnerAmper report no disagreements and no unresolved issues; however, prior audit reports noted a going‑concern explanatory paragraph, and investors should continue to monitor future filings for a new auditor engagement, any changes to audit opinions, and ongoing disclosures about liquidity and remediation of past control issues.